Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group. 1995

D W Newling, and M R Robinson, and P H Smith, and D Byar, and R Lockwood, and I Stevens, and M De Pauw, and R Sylvester
Free University Hospital, Department of Urology, Amsterdam, The Netherlands.

This double-blind randomised phase III trial was designed to assess the effect of pyridoxine administration on the recurrence of Ta and T1 transitional cell tumours of the bladder. The trial accrued 291 patients and showed no significant difference between the pyridoxine and placebo treatment groups with respect to the time to first recurrence or the recurrence rate. Adjustment for the main prognostic factors, namely the recurrence rate prior to entry, the number of tumours at entry, the G grade and the levels of the tryptophan metabolites kynurenine plus acetyl kynurenine at entry do not change the overall conclusions.

UI MeSH Term Description Entries
D007736 Kynurenic Acid A broad-spectrum excitatory amino acid antagonist used as a research tool. Kynurenate,Acid, Kynurenic
D007737 Kynurenine A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011736 Pyridoxine The 4-methanol form of VITAMIN B 6 which is converted to PYRIDOXAL PHOSPHATE which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. Although pyridoxine and Vitamin B 6 are still frequently used as synonyms, especially by medical researchers, this practice is erroneous and sometimes misleading (EE Snell; Ann NY Acad Sci, vol 585 pg 1, 1990). Pyridoxin,Pyridoxine Hydrochloride,Pyridoxol,Pyridoxol Hydrochloride,Rodex
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas

Related Publications

D W Newling, and M R Robinson, and P H Smith, and D Byar, and R Lockwood, and I Stevens, and M De Pauw, and R Sylvester
April 1999, European urology,
D W Newling, and M R Robinson, and P H Smith, and D Byar, and R Lockwood, and I Stevens, and M De Pauw, and R Sylvester
September 1985, European journal of cancer & clinical oncology,
D W Newling, and M R Robinson, and P H Smith, and D Byar, and R Lockwood, and I Stevens, and M De Pauw, and R Sylvester
January 1988, Progress in clinical and biological research,
D W Newling, and M R Robinson, and P H Smith, and D Byar, and R Lockwood, and I Stevens, and M De Pauw, and R Sylvester
January 1998, European urology,
D W Newling, and M R Robinson, and P H Smith, and D Byar, and R Lockwood, and I Stevens, and M De Pauw, and R Sylvester
April 1983, European journal of cancer & clinical oncology,
D W Newling, and M R Robinson, and P H Smith, and D Byar, and R Lockwood, and I Stevens, and M De Pauw, and R Sylvester
October 1984, European journal of cancer & clinical oncology,
D W Newling, and M R Robinson, and P H Smith, and D Byar, and R Lockwood, and I Stevens, and M De Pauw, and R Sylvester
August 1989, European journal of cancer & clinical oncology,
D W Newling, and M R Robinson, and P H Smith, and D Byar, and R Lockwood, and I Stevens, and M De Pauw, and R Sylvester
December 1989, European journal of cancer & clinical oncology,
Copied contents to your clipboard!